

# Stefano Bianchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9087349/publications.pdf>

Version: 2024-02-01

36  
papers

2,702  
citations

377584

21  
h-index

466096

32  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2353  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting hyperkalemia in patients with acute kidney injury: time for a change of weaponry. Internal and Emergency Medicine, 2020, 15, 371-372.	1.0	1
2	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2020, 33, 417-430.	0.9	8
3	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2019, 32, 499-516.	0.9	63
4	Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrology Dialysis Transplantation, 2019, 34, iii51-iii61.	0.4	11
5	Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. Journal of Nephrology, 2018, 31, 653-664.	0.9	35
6	A Delphi consensus panel on nutritional therapy in chronic kidney disease. Journal of Nephrology, 2016, 29, 593-602.	0.9	20
7	The renal effects of mineralocorticoid receptor antagonists. International Journal of Cardiology, 2015, 200, 20-24.	0.8	14
8	The CKD Patient with Dyslipidemia. , 2014, , 93-110.		0
9	Relationship between hypertension, diabetes and proteinuria in rural and urban households in Yemen. Journal of Human Hypertension, 2013, 27, 572-579.	1.0	12
10	Divert to ULTRA: Differences in Infused Volumes and Clearance in Two On-Line Hemodiafiltration Treatments. International Journal of Artificial Organs, 2012, 35, 435-443.	0.7	15
11	Statins and Lipid- Lowering Strategies in Cardiorenal Patients. Contributions To Nephrology, 2011, 171, 143-150.	1.1	7
12	A Vitamin E-Coated Polysulfone Membrane Reduces Serum Levels of Inflammatory Markers and Resistance to Erythropoietin-Stimulating Agents in Hemodialysis Patients: Results of a Randomized Cross-Over Multicenter Trial. Blood Purification, 2011, 32, 7-14.	0.9	46
13	Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. Journal of Nephrology, 2011, 24, 550-553.	0.9	9
14	Intensive Versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases. American Journal of Kidney Diseases, 2010, 55, 671-681.	2.1	29
15	Increased cardiovascular events in hypertensive patients with insulin resistance: A 13-year follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 314-319.	1.1	9
16	Metabolic Risk Factors and Markers of Cardiovascular and Renal Damage in Overweight Subjects. American Journal of Hypertension, 2006, 19, 426-431.	1.0	12
17	Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International, 2006, 70, 2116-2123.	2.6	282
18	Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study. American Journal of Kidney Diseases, 2005, 46, 45-51.	2.1	128

#	ARTICLE	IF	CITATIONS
19	A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 41, 565-570.	2.1	295
20	Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. <i>Journal of Human Hypertension</i> , 2003, 17, 13-20.	1.0	17
21	Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 143-147.	1.0	30
22	Microalbuminuria in Essential Hypertension. Significance for the Cardiovascular and Renal Systems. , 2000, , 575-586.		0
23	Association between hyperlipidemia and microalbuminuria in essential hypertension. <i>Kidney International</i> , 1999, 56, S10-S13.	2.6	32
24	Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. <i>American Journal of Kidney Diseases</i> , 1999, 34, 973-995.	2.1	160
25	Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. <i>Journal of Hypertension</i> , 1998, 16, 1325-1333.	0.3	285
26	Microalbuminuria in Patients with Essential Hypertension. Cardiovascular and Renal Implications. , 1998, , 569-584.		1
27	Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: Role of insulin. <i>American Journal of Hypertension</i> , 1996, 9, 24-32.	1.0	87
28	Effect of insulin on renal sodium and uric acid handling in essential hypertension. <i>American Journal of Hypertension</i> , 1996, 9, 746-752.	1.0	248
29	Salt Intake and Plasma Atrial Natriuretic Peptide and Nitric Oxide in Hypertension. <i>Hypertension</i> , 1996, 28, 335-340.	1.3	80
30	Insulin Resistance in Microalbuminuric Hypertension. <i>Hypertension</i> , 1995, 26, 789-795.	1.3	72
31	Diurnal Variations of Blood Pressure and Microalbuminuria in Essential Hypertension. <i>American Journal of Hypertension</i> , 1994, 7, 23-29.	1.0	368
32	Lone-Term Effects of a Converting Enzyme Inhibitor and a Calcium Channel Blocker on Urinary Albumin Excretion in Patients With Essential Hypertension. <i>American Journal of Hypertension</i> , 1993, 6, 108-113.	1.0	36
33	Prevalence of Microalbuminuria in a Large Population of Patients with Mild to Moderate Essential Hypertension. <i>Nephron</i> , 1992, 61, 94-97.	0.9	126
34	Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. <i>American Journal of Medicine</i> , 1992, 93, 525-528.	0.6	71
35	Microalbuminuria in Patients With Essential Hypertension. <i>American Journal of Hypertension</i> , 1991, 4, 291-296.	1.0	46
36	Long-Term Effects of Enalapril and Nifedipine on Urinary Albumin Excretion in Patients with Chronic Renal Insufficiency: A 1-Year Follow-Up. <i>American Journal of Nephrology</i> , 1991, 11, 131-137.	1.4	47